Abiopharma

🔍 Fabiano Amanda (Executive)

Company: Nakamoto Inc. (NAKA)

Report Date: 2026-08-21

Detailed Transactions and Holdings:

• Acquired 70,821 shares of Common Stock (Direct)
  Date: 2026-08-21 | Code: A | equity_swap_involved: 0 | shares_owned_after: 174,204.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: Reflects restricted stock units ("RSUs") that shall time-vest over a 2-year period commencing on August 14, 2026, with no vesting during the first 12 months (the "RSU Cliff Period"), and thereafter, twenty-five percent (25%) of the RSUs shall vest upon completion of the RSU Cliff Period, with the remaining seventy-five percent (75%) vesting in equal quarterly installments over the following 12 months, subject to the RSU award agreement and the reporting person's continued service to Nakamoto Inc. (the "Issuer") through each applicable vesting date.
• F2: Effective May 22, 2026, the Issuer effected a 1-for-40 reverse stock split of the Issuer's Common Stock, par value $0.001 per share. The number of securities reported herein has been adjusted to reflect the reverse stock split.